Amnestic Mild Cognitive Impairment Clinical Trial
Official title:
A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure cognitive function. This study will also explore the safety and tolerability of AQW051 in these patients.
Status | Terminated |
Enrollment | 54 |
Est. completion date | |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 55 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Willing and able to give written informed consent - Meet the diagnostic criteria for either amnestic mild cognitive impairment (amnestic MCI) or mild Alzheimer's Disease (AD). - Structural brain scan within the last 6 months prior to randomization that indicates no other underlying disease, in particular no evidence for vascular pathology except for normal age-related white matter/incidental white matter changes which is normal for this age group. - Daily contact with a primary caregiver/partner Exclusion Criteria: - Immune therapy targeting Alzheimer beta amyloid within the last 12 months - Institutionalized - Disability that may prevent completion of all study requirements (e.g., blindness, deafness, or communication difficulty) - Reported use of tobacco products in the previous 3 months or have a urine cotinine level greater than 500 ng/ml - Past medical history of clinically significant electrocardiogram (ECG) abnormalities or a family history (grandparents, parents, and siblings) of prolonged QT-interval syndrome - History or current diagnosis of conditions specified in the protocol. Other protocol-defined inclusion/exclusion criteria may apply. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Novartis Investigator Site | Halifax | |
Canada | Novartis Investigator Site | Montreal | |
Canada | Novartis Investigator Site | Toronto | |
South Africa | Novartis Investigator Site | Bloemfontein | |
South Africa | Novartis Investigator Site | George | |
South Africa | Novartis Investigator Site | Port Elizabeth | |
United Kingdom | Novartis Investigator Site | Blackpool | |
United Kingdom | Novartis Investigator Site | Epping | |
United Kingdom | Novartis Investigator Site | Glasgow | |
United Kingdom | Novartis Investigator Site | Manchester | |
United Kingdom | Novartis Investigator Site | Southampton | |
United Kingdom | Novartis Investigator Site | Swindon |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
Canada, South Africa, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Validated computerized cognitive assessment scores | Througout the study | No | |
Secondary | Validated computerized cognitive assessment scores, the different scores from the Alzheimer's Disease Assessment Score-cognitive subscale (ADAS-Cog), Quality of Life-Alzheimer disease scale and the Disability Assessment for Dementia scale | Throughout the study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01525368 -
Outcome Predictors of a Cognitive Intervention in aMCI
|
N/A | |
Completed |
NCT00785759 -
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
|
Phase 2 | |
Recruiting |
NCT05903573 -
Training Response Artificial Intelligence Network (TRAIN)
|
N/A | |
Completed |
NCT02562989 -
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
|
Phase 1 | |
Completed |
NCT02910739 -
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
|
Phase 1 | |
Completed |
NCT04185298 -
mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment
|
N/A | |
Not yet recruiting |
NCT04103463 -
Interactive Stepping Exercise on Memory
|
N/A | |
Recruiting |
NCT04063956 -
COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT
|
N/A | |
Terminated |
NCT01953601 -
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
|
Phase 3 | |
Recruiting |
NCT06041152 -
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
|
Phase 2 | |
Completed |
NCT01962038 -
A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT06444568 -
Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments
|
N/A | |
Recruiting |
NCT03133052 -
CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)
|
N/A | |
Not yet recruiting |
NCT05987007 -
Sleep Interventions and Neurocognitive Outcomes
|
N/A | |
Recruiting |
NCT04240561 -
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
|
N/A | |
Completed |
NCT01767909 -
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
|
Phase 2/Phase 3 | |
Terminated |
NCT01072812 -
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
|
Phase 1 | |
Completed |
NCT00643266 -
Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT04504630 -
Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury
|
N/A | |
Recruiting |
NCT05446584 -
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
|
Phase 2 |